Sugi Predict

Sugi Predict / Compounds / SCHEMBL733334

SCHEMBL733334

SCHEMBL733334

Nc1c(Cl)cccc1C(=O)Nc1ccccc1Cl

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 2/20 0.74
▸ HPGD P15428 1/20 0.74
▸ CYP2C19 P33261 1/20 0.74
▸ KDM4E B2RXH2 3/20 0.57
▸ RAB9A P51151 5/20 0.55
▸ NPC1 O15118 5/20 0.55
▸ ALDH1A1 P00352 2/20 0.55
▸ ATM Q13315 2/20 0.51
▸ POLB P06746 1/20 0.51
▸ CASP3 P42574 1/20 0.51
▸ SENP8 Q96LD8 1/20 0.51
▸ SENP7 Q9BQF6 1/20 0.51
▸ SENP6 Q9GZR1 1/20 0.51
▸ KDR P35968 1/20 0.51
▸ EPHB3 P54753 2/20 0.50
▸ L3MBTL1 Q9Y468 2/20 0.50
▸ GLA P06280 1/20 0.50
▸ RIPK2 O43353 1/20 0.50
▸ LCK P06239 1/20 0.50
▸ PABPC1 P11940 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28945955 0.92 CYP1A2 (0.68) CYP1A2HPGDCYP2C19KDM4ERAB9A
SCHEMBL31680566 0.87 CYP1A2 (0.89) CYP1A2HPGDCYP2C19KDM4ERAB9A
SCHEMBL28015342 0.86 CYP1A2 (0.74) CYP1A2HPGDCYP2C19KDM4ERAB9A
SCHEMBL30726102 0.86 CYP1A2 (0.74) CYP1A2HPGDCYP2C19KDM4ERAB9A
SCHEMBL734924 0.85 CYP1A2 (0.59) CYP1A2HPGDCYP2C19KDM4EALDH1A1
SCHEMBL15229156 0.85 SMO (0.59) CYP1A2HPGDCYP2C19KDM4ERAB9A
SCHEMBL17904696 0.85 NPC1 (0.61) CYP1A2HPGDCYP2C19KDM4ERAB9A
SCHEMBL16320319 0.82 MAPT (0.51) CYP1A2HPGDCYP2C19KDM4ERAB9A
SCHEMBL24449161 0.81 CYP1A2 (0.77) CYP1A2HPGDCYP2C19KDM4ERAB9A
SCHEMBL2700280 0.81 CYP1A2 (0.77) CYP1A2HPGDCYP2C19KDM4ERAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10695349-B2 Inhibitors of human phosphatidylinositol 3-kinase delta ICOS CORPORATION (US) 2020-06-30 — — US disclosed
EP-3029041-B1 INHIBITORS OF HUMAN PHOSPHATIDYL-INOSITOL 3-KINASE DELTA ICOS CORP (US) 2020-03-04 — — EP disclosed
US-20200061062-A1 INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA ICOS CORPORATION 2020-02-27 — — US disclosed
US-10398695-B2 Inhibitors of human phosphatidylinositol 3-kinase delta ICOS CORPORATION (US) 2019-09-03 — — US disclosed
US-20180360832-A1 INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA ICOS CORPORATION 2018-12-20 — — US disclosed
US-10010550-B2 Inhibitors of human phosphatidylinositol 3-kinase delta ICOS CORPORATION (US) 2018-07-03 — — US disclosed
US-20170340633-A1 INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA ICOS CORPORATION 2017-11-30 — — US disclosed
US-20170049772-A1 INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA ICOS CORPORATION 2017-02-23 — — US disclosed
US-9487772-B2 Inhibitors of human phosphatidylinositol 3-kinase delta ICOS CORPORATION (US) 2016-11-08 — — US disclosed
EP-3029041-A1 INHIBITORS OF HUMAN PHOSPHATIDYL-INOSITOL 3-KINASE DELTA ICOS Corporation (US) 2016-06-08 — — EP disclosed
US-6800620-B2 CONTACTING LEUKOCYTES, OSTEOCLASTS WITH AN ENZYME INHIBITORS, A 9H-PURIN-3H-QUINAZOLIN-4-ONE DERIVATIVES, TREATING BONE-RESORPTION DISORDER, ANTIPROLIFERATIVE AGENTS TREATING LEUKEMIA CELLS ICOS 2004-10-05 — — US disclosed
EP-1438052-A1 INHIBITORS OF HUMAN PHOSPHATIDYL−INOSITOL 3−KINASE DELTA ICOS CORPORATION (US) 2004-07-21 — — EP disclosed
US-6667300-B2 Purinyl substituted quinazoline-4-one derivatives ICOS CORPORATION 2003-12-23 — — US disclosed
US-20030195211-A1 Inhibitors of human phosphatidylinositol 3-kinase delta ICOS CORPORATION 2003-10-16 — — US disclosed
CN-1440408-A Inhibitors of human phosphatidylinositol 3-kinase delta ICOS CORP (US) 2003-09-03 — — CN disclosed
WO-2003035075-A1 INHIBITORS OF HUMAN PHOSPHATIDYL-INOSITOL 3-KINASE DELTA ICOS CORPORATION (US) 2003-05-01 — — WO disclosed
US-6518277-B1 Disrupting leukocyte function ICOS CORPORATION 2003-02-11 — — US disclosed
EP-1278748-A2 INHIBITORS OF HUMAN PHOSPHATIDYL-INOSITOL 3-KINASE DELTA ICOS CORPORATION (US) 2003-01-29 — — EP disclosed
US-20020161014-A1 Purinyl substituted quinazoline-4-one derivatives ICOS CORPORATION, A DELAWARE CORPORATION 2002-10-31 — — US disclosed
WO-2001081346-A2 INHIBITORS OF HUMAN PHOSPHATIDYL-INOSITOL 3-KINASE DELTA ICOS CORPORATION (US) 2001-11-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170340633-A1 INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA PIK3CD, PIK3CA, PIK3CG CYP1A2 3429/4885HPGD 2638/4885CYP2C19 2756/4885
US-20180360832-A1 INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA PIK3CD, PIK3CA, PIK3CG CYP1A2 3429/4885HPGD 2638/4885CYP2C19 2756/4885
US-20020161014-A1 Purinyl substituted quinazoline-4-one derivatives PIK3CD, PIK3CA, PIK3CG CYP1A2 2992/4885HPGD 1589/4885CYP2C19 2426/4885
US-20170049772-A1 INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA PIK3CD, PIK3CA, PIK3CG CYP1A2 3986/4885HPGD 2546/4885CYP2C19 3431/4885
US-20200061062-A1 INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA PIK3CD, PIK3CA, PIK3CG CYP1A2 3429/4885HPGD 2638/4885CYP2C19 2756/4885
US-20030195211-A1 Inhibitors of human phosphatidylinositol 3-kinase delta PIK3CD, PIK3CA, PIK3CG CYP1A2 3168/4885HPGD 2112/4885CYP2C19 2428/4885
US-10695349-B2 Inhibitors of human phosphatidylinositol 3-kinase delta PIK3CD, PIK3CA, PIK3CG CYP1A2 3429/4885HPGD 2638/4885CYP2C19 2756/4885
US-10010550-B2 Inhibitors of human phosphatidylinositol 3-kinase delta PIK3CD, PIK3CA, PIK3CG CYP1A2 3429/4885HPGD 2638/4885CYP2C19 2756/4885
US-10398695-B2 Inhibitors of human phosphatidylinositol 3-kinase delta PIK3CD, PIK3CA, PIK3CG CYP1A2 3429/4885HPGD 2638/4885CYP2C19 2756/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.